ロード中...
Transforming the early drug development paradigm at the National Cancer Institute: The formation of NCI’s Experimental Therapeutics Clinical Trials Network (ETCTN)
Early drug development for cancer requires broad collaboration and skilled clinical investigators to enable enrollment of patients whose tumors have defined molecular profiles. To respond to these challenges, the National Cancer Institute (NCI) transformed its 60-year old early phase drug developmen...
保存先:
| 出版年: | Clin Cancer Res |
|---|---|
| 主要な著者: | , , , , , , , , , , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
2019
|
| 主題: | |
| オンライン・アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6891162/ https://ncbi.nlm.nih.gov/pubmed/31439585 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-19-1754 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|